Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Gutekunst
Imatinib Mesylate Induces Cisplatin Hypersensitivity in BCR-Abl+ Cells by Differential Modulation of P53 Transcriptional and Proapoptotic Activity
Cancer Research
Cancer Research
Oncology
Related publications
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Cancer Research
Cancer Research
Oncology
An Amino-Acid Switch in the BCR-ABL Kinase Domain Modifies Sensitivity to Imatinib Mesylate
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
In Vitro and in Vivo Activity of SKI-606, a Novel SRC-Abl Inhibitor, Against Imatinib-Resistant BCR-Abl+ Neoplastic Cells
Cancer Research
Cancer Research
Oncology
Prognostic Significance of Micro RNA 150 Marker in BCR-ABL Positive Chronic Myeloid Leukaemia Patients on Imatinib Mesylate
International Journal of Contemporary Pediatrics
NPB001-05 Inhibits BCR-Abl Kinase Leading to Apoptosis of Imatinib-Resistant Cells
Frontiers in Bioscience - Elite
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
Contribution of BCR-ABL Kinase Domain Mutations to Imatinib Mesylate Resistance in Philadelphia Chromosome Positive Malaysian Chronic Myeloid Leukemia Patients
Hematology Reports
Hematology
Semi‑random Mutagenesis Profile of BCR‑ABL During Imatinib Resistance Acquirement in K562 Cells
Molecular Medicine Reports
Oncology
Genetics
Molecular Biology
Biochemistry
Cancer Research
Molecular Medicine
Nilotinib Significantly Induces Apoptosis in Imatinib Resistant K562 Cells With Wild-Type BCR–ABL, as Effectively as in Parental Sensitive Counterparts
Hematology
Hematology
MPT0B169, a New Antitubulin Agent, Inhibits BCR-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
PLoS ONE
Multidisciplinary
